Ayass Research Institute - F420 Program

Article Published in MDPI: 6 August 2024. AYA22A Aptamers Mitigate Peanut Allergenicity: Insights from Degranulation Assays and Modulating Immune Responses.
Food allergy, particularly peanut allergy (PA), is a growing health concern affecting millions globally. PA can lead to severe reactions, including fatal anaphylaxis. Despite the availability of FDA-approved therapies like Palforzia, a cure remains elusive. Current immunotherapies show promise but lack a definitive cure. This study applies an established computational biology tool to design aptamers targeting Ara h1 and Ara h2. The in silico design aims to streamline the selection process, enabling cost-effective and rapid identification of aptamer candidates. The developed aptamers (AYA22A, including AYA22AR321, AYA22AR211, and AYA22AR524), demonstrated efficacy in inhibiting degranulation of RBL-2H3 cells (rat basophilic leukemia cell line) in vitro. They showed promise in neutralizing peanut allergen-induced immune responses. The selected aptamers inhibited degranulation in RBL-2H3 cells, addressing concerns in raw peanuts. Moreover, these aptamers demonstrated stability and effectiveness in peanut plant seeds and commercial products. Our aptamers exhibited potential in modulating immune responses associated with peanut allergy. They influenced Th1/Th2 balance, indicating a role in cytokine regulation. In vitro studies also showed the aptamers’ impact on immune cell expression and cytokine production, resembling responses observed with established immunotherapies. The findings suggest AYA22A aptamers as a potential therapeutic option for peanut allergy, providing a basis for further in vivo investigations.

AYA22A Aptamers Mitigate Peanut Allergenicity: Insights from Degranulation Assays and Modulating Immune Responses Food allergy, particularly peanut allergy (PA), is a growing health concern affecting millions globally. PA can lead to severe reactions, including fatal anaphylaxis. Despite the availability of FDA-approved therapies like Palforzia, a cure remains elusive. Current immunotherapies show promise but l...

Early Detection of Cervical Cancer. Molecular analysis. Comprehensive Assay captures various aspects of cervical cancer biology. To assure prompt treatment and significantly improve the chances of successful recovery and survival call 888-889-4770 or visit F420.ai.

We can put an end to TRIAL-AND-ERROR approach to medical treatment.

Early Detection of Cervical Cancer: Comprehensive Molecular Assay for Cervical Cancer Screening. Molecular analysis using minimally invasive sampling, which involves studying the complete set of RNA transcripts produced by the genome of a particular cell or tissue, offers several advantages in the early detection of cervical cancer.

Do you have diabetes? What Type of diabetes? Transcriptome Analysis will help you to figure this out!
If the DIABETES is precisely characterized and right treatment identified, a good resolution is far more likely! Explore your options. Powered by AI and Machine Learning. Visit our website for more information: F420.ai

Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A

Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A Recent strides in immunotherapy have illuminated the crucial role of CTLA-4 and PD-1/PD-L1 pathways in contemporary oncology, presenting both promises and challenges in response rates and adverse effects. This study employs a computational biology tool (in silico approach) to craft aptamers capable....

Transcriptome Analysis. If the DIABETES is precisely characterized and right treatment identified, a good resolution is far more likely! Explore your options. Powered by AI and Machine Learning. Visit our website for more information: F420.ai

Transcriptome Analysis. Powered by AI and Machine Learning.
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Fibromyalgia, Systemic Sclerosis, Crohn Disease, Multiple Sclerosis, Sjögren's Syndrome, and others.
Visit our website for more information: F420.ai